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Abstract 
Results from in vivo and from serum-free primary cultures of Ehrlich cells suggest hat the expression of mitogen-regulated protein/proliferin 
(MRP/PLF) mRNAs is not essential for proliferation of this murine tumor. Two sizes for MRP/PRL-related open reading frames (ORFs) have been 
detected by reverse transcription/PCR amplification. They are almost identical to that reported for PLF-1; but 20% of the amplified cDNA included 
a shorter ORF, which lacks the entire sequence corresponding to that of the exon 3 of the mrplplfgenes. Ehrlich carcinoma may represent a good 
model to study regulation of expression and physiological roles of MRP/PLFs in vivo. 
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1. Introduction 
Proliferins (PLFs) are members of the growth 
hormone/prolactin (GH/PRL) family [I] identified with 
mitogen-regulated proteins (MRPs) [2]. They are ex- 
pressed and secreted by different murine cultured cell 
lines and trophoblastic giant cells in vivo [2,3]. The ma- 
ture proteins are glycopeptides which bind to the cation- 
independent mannose-phosphate r ceptor [4], and to a 
second receptor detected in placenta, uterus and mam- 
mary gland of pregnant mice [5]. The involvement of 
MPR/PLF expression in proliferation, differentiation, 
immortalization and transformation of several mouse 
embryo cultured cells have also been studied [6-81. Nev- 
ertheless, the expression of MRP/PLF does not always 
correlate with cell proliferation and physiological roles 
of these proteins have not been completely ascertained, 
being autocrine and paracrine functions hypothesized 
for these proteins [l-8]. Mouse chromosome 13 contains 
approximately six copies of mrplplf genes (as well as 
prolactin and placental actogen genes [9]. All the mem- 
bers of the GHIPRL family are derived from a common 
precursor and have similar intron/exon boundaries; 
three mrplplf promoters are known so far to have slight 
differences among them [IO, 1 I]. In addition, other prolif- 
erin-related transcripts are detected in mouse placenta, 
which follow a different time course than the initially 
observed for proliferin [12]. Transcriptional and post- 
transcriptional mechanisms are involved to control the 
MRP/PLF expression [I I, 13-I 51. Three different MRP/ 
PLF sequences have been deduced (PLF-I, PLF-2, 
*Corresponding author. Fax: (34) (52) 132000. 
MRP/PLF-3) [IO], some authors doubt that the physio- 
logical roles of each gene product are identical [2,5,6,13]. 
Using a PLF-2 cDNA from BALB/c mouse placenta 
as a probe [ 161, hybridizable mRNA levels have been 
determined during Ehrlich carcinoma progression in 
vivo and primary cultures. By reverse transcription/ 
polymerase chain reaction (RT/PCR) experiments, we 
have detected that two different PLF-1 open reading 
frames (ORFs) are expressed by these cells. Results sug- 
gest that expression of MRP/PLF is not related to tumor 
proliferation in this murine cancer model. 
2. Materials and methods 
2.1. Cell cultures 
A hyperdiploid Lettre strain of Ehrlich ascitic carcinoma was main- 
tained in 2-month-old Swiss mice, as reported previously [17]. The 
growth curve for the tumor has also been described elsewhere [IS]; life 
span of the animals is 16 f 1 days. On different days, cells were har- 
vested, washed twice and frozen in sterile conditions for RNA extrac- 
tion. Primary cultures of Ehrlich cells were carried out in Dulbecco’s 
Modified Eagle’s medium: Ham’s F12 medium (1 : 1) supplemented 
with 0.2% bovine serum albumin and antibiotics as described previ- 
ously [19]. 
2.2. Northern blot analysis 
Total RNA (10 pg) isolated by the acid guanidinium-phenol<hloro- 
form method, was fractionated by formaldehyde-agarose g l electro- 
phoresis and transferred to Nylon membranes [19,20]. The transferred 
RNA was hybridized to a proliferin cDNA from mouse placenta con- 
taining the full-length open reading frame for the PLF-2 sequence [16]. 
Filters were rehybridized with the glyceraldehyde-3-phosphate dehy- 
drogenase (GAPDH, EC 1.1.1.8) and ornithine decarboxylase (ODC, 
EC 4.1.1.17) probes described previously [12]. GAPDH mRNA 
(a housekeeping ene product) was detected as an internal control; 
ODC mRNA was used as a poorly translated and proliferation-related 
message [19]. Probes were labeled by Multiprime DNA Labeling Sys- 
tem with [cc-‘*P]dCTP (Amersham Iberica, Spain). Each experiment was 
repeated for several times from different cell batches, and similar results 
were obtained. Representative results are shown in figures. Autoradi- 
ographs were analyzed by transmittance densitometry using a Hoefer 
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GS 300 scanning densitometer and the GS370 I-D Electrophoresis 
Data System version 2.3 (Hoefer Scientific, USA). 
2.3. Polysome isolation and fractionation 
Ehrlich carcinoma cells were harvested, washed twice in the phos- 
phate-buffered saline [17], and lysed in 10 mM HEPES, 1.5 mM magne- 
sium acetate, 10 mM KCI, 7 mM /I-mercaptoethanol, lOO,&ml cyclo- 
heximide, 50 U/ml ribonuclease inhibitor from human placenta, 1% 
Nonidet P-40 and 1% deoxycholate (50 x lo6 cells/l.5 ml, 15 min, pH 
7.5,4”C). After centrifugation (8,000 rpm, 10 min, 4°C) supernatants 
(1 ml) were layered onto a 1040% (w/v) linear sucrose gradient pre- 
pared in 10 mM HEPES, 50 mM magnesium acetate, 0.5 M KCl, 7 mM 
/?-mercaptoethanol, 100 ,&ml cycloheximide and centrifuged again at 
w2r = 9.02 x 10’” rad*/s in a Beckman SW 28 rotor at 5°C. Then, 1.5 ml 
fractions were collected and absorbance was measured at 260 nm. 
Thereafter, three consecutive fractions were phenol extracted, precipi- 
tated with ethanol, dried and solved in equal volumes of diethylpyrocar- 
bonate-treated water. Samples were divided in two aliquots and parallel 
electrophoresed as described above. From each sample, an aliquot was 
transferred, baked and hybridized, the other one was used to confirm 
the integrity of RNA (based on appearance of ribosomal RNA bands). 
2.4. RTIPCR ampll$cation and sequencing 
Samples of mRNA were obtained using Mini Fast Track System 
(EcoGen, UK). M-MuLV reverse transcriptase (Boehringer 
Mannheim, Germany) and AmphTaq DNA polymerase (Perkin Elmer- 
Cetus. USA) were used. The basic urotocol has been described by Rolfs 
et al. [21]. Primers were designed to be complementary to reported 
genomic and cDNA sequences for MRPlPLFs [I ,2,4,7]: primer I, from 
63 to 47 bases upstream of the translation initiation codon (5’- 
TTCCAACTCCAGTIAAG-3’); primer 2, from 18 to 5 bases down- 
stream the stop codon plus a- Pstl site (5’-AGCTGCAGAGCA- 
CATGAAAGA-3’). Amnlification was allowed for 22 cvcles: 93°C for 
1 min, 55°C for 3d s, 72°C for 1 min (final extension Id min); after 22 
amplification cycles, the number of initial templates is expected to be 
exponentially-related to the observed product amount [5,21]. For 
Southern blotting, Nytrdn (Schleicher and Schuell, Germany) and the 
PLF-2 probe described above was used. There is a PstI internal site at 
8-3 bo unstream the translation initiation codon in every MRPlPLF 
sequence&known so far; thus, RT/PCR products from two-different cell 
sample mRNAs (A and B) were purified from agarose gel by the Gene 
Clean method, digested with PstI and subcloned using PstI-digested 
dephosphorylated pGEM32 vector (Promega, USA). Both strand se- 
quencing was performed as previously reported [20] and using an ALF 
DNA sequencer (Pharmacia, Sweden). 
3. Results and discussion 
Serum, several growth factors and virus-mediated on- 
cogenic transformation induce PLF-1 expression in 3T3 
fibroblasts, reaching a peak at the onset of DNA synthe- 
sis [l]; maximum PLF-2 expression in mouse placenta 
also occurs during placental growth [3,4,16]. Neverthe- 
less, MRPlPLFs do not seem to be essential factors for 
proliferation of every cultured mouse embryonic cell line 
[2,7]. Krebs tumor cells growing in vivo also express 
PLF-1 on day 10 after transplantation [l]. However, as 
far as we know, the PLF expression along tumor pro- 
gression in vivo has not been studied. Fig. 1 shows results 
of Northern blot experiments, using samples collected on 
different days after Ehrlich carcinoma transplantation. 
A PLF-hybridizable mRNA is detected from day 8 on- 
wards, reaching the maximum level on day 12, when the 
tumor has reached the plateau phase of growth. The 
PLF-2 probe recognized a smear band of about 1 kb, as 
reported for MRP/PLF messages detected in different 
embryonic cell lines [1,7,16]. Working with serum stimu- 
lated BALB/c 3T3 fibroblasts, Linzer and Wilder [14] 
suggest that this heterogeneity can be due to post-tran- 
scriptional events (i.e. different poly(A) tail lengths). No 
hybridization signal could be detected by the PLF-2 
A 
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Fig. 1. Evolution of the PLF mRNA levels during in vivo progression 
of Ehrlich ascitic tumor. (A) Total cell numbers obtained during tumor 
progression in vivo on different days after tumor inoculation (5 x IO6 
cells/mouse). (B) Northern analysis of RNA from the Ehrlich cells 
shown in (A) on day 6 (lane I), day 8 (lane 2) day 10 (lane 3) day I2 
(lane 4) and day 14 (lane 5) after tumor transplantation. A single 
membrane was hybridized to cDNA probes for PLF, GAPDH and 
ODC. Relative hybridization signals for PLF mRNA normalized to 
those of GAPDH were: 0 (days 4 and 6) 0.16 (day 8). 0.72 (day IO), 
1 .OO (day 12) 0.90 (day 14). 
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probe even after longer exposure of filters containing 
RNA samples from cells harvested on day 4 and day 6 
after the Ehrlich carcinoma transplantation, when the 
tumor is in the exponential phase of growth (Fig. 1A and 
[18]). In contrast to the results obtained with BALB/c 
3T3 fibroblasts [l] or mouse placenta [16], high molecu- 
lar size MRP/PLF mRNA precursors were not detecta- 
ble either at any tested condition. The signals obtained 
after rehybridization of the filters with an internal con- 
trol probe (GAPDH) and with a specific ODC probe is 
also shown for comparison. As can be observed in Fig. 
lB, ODC and MRP/PLF mRNAs follow a different 
time-course throughout the Ehrlich tumor progression. 
A 
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The relative distribution of free messenger and mes- 
senger associated with high density polysomes give a 
validated indication of the actual translatability of an 
mRNA [22]. In Fig. 2A, a representative result of the 
PLF 2-hybridizable mRNA distribution on isolated pol- 
ysome fractions from Ehrlich cells harvested at plateau 
phase of growth is shown: most of the signal intensity 
was associated with polysome fractions (> 150 S) and less 
than 20% of the signal was detected as free mRNA. 
GAPDH and ODC mRNAs were also detected on the 
same filters, both messages are longer in size than MRP/ 
PLF mRNA; however, they appeared in a major extent 
as free mRNAs or associated to a lower number of ribo- 
somes (Fig. 2B). The poorly translated ODC mRNAs 
[ 191 and the MRP/PLF-related mRNAs exhibited oppo- 
site distribution patterns on polysome profiles from rest- 
ing Ehrlich carcinoma cells. Results suggest that Ehrlich 
carcinoma actively translates proliferin-related mRNAs 
at plateau phase of growth in vivo. 
090 
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Ehrlich carcinoma cells are able to proliferate in the 
absence of serum. The possibility of a relationship be- 
tween MRP/PLF expression and cell proliferation in the 
absence of the host interferences was tested on serum- 
free Ehrlich cell cultures. The seeded cells had been har- 
vested on day 6 (exponential phase of growth) or on day 
10 (plateau-phase of growth) after tumor transplanta- 
tion. At different times, cultured samples were obtained 
and PLF 2-hybridizable mRNA levels were detected by 
Northern blotting at different times. As observed in Fig. 
3, MRP/PLF-related mRNA levels were not increased 
during proliferation of primary serum-free cultures of 
Ehrlich cells when seeded cells had been harvested at 
plateau-phase of growth in vivo. In addition, no PLF 
2-hybridizable mRNA could be detected in serum-free 
cultures when seeded cells came from day 6 Ehrlich cells 
growing in vivo. Therefore, autocrine factors do not 
seem to have any effect inducing the MRP/PLF expres- 
sion in our model; and in agreement with the results 
observed in vivo, proliferin expression does not seem to 
be essential for Ehrlich cell growth, as also reported for 
other murine embryonic cells [2,7]. 
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Fig. 2. Distribution of PLF mRNAs in polysome profiles from Ehrlich 
cells in plateau phase of growth. (A) Absorbance profiles measured at 
260 nm on individual fractions (1.5 ml). Arrows indicate sedimentation 
coefficients corresponding to the fractions at 5°C. Northern blot anal- 
ysis of MRPlPLF mRNA from pooled fractions; lane 1 (fractions l-3), 
lane 2 (fractions 46), lane 3 (fractions 7-9) lane 4 (fractions l&12), 
lane 5 (fractions 13-15), lane 6 (fractions l&18), lane 7 (fractions 
19-21) lane 8 (fractions 22-24) is also shown on the profile. (B) Distri- 
bution of the hybridization signal intensities for MRPIPLF, GAPDH 
and ODC mRNAs on the same filter. The sum of the signal intensities 
for each mRNA was considered 100%. 
As stated above, several copies of mrplplf genes are 
present in the mouse genome. Once the evolution of 
PLF-2-hybridable RNA levels had been observed in 
Ehrlich cells growing in vivo and in vitro, the following 
aim was to determine the similarity between the PLF 
expressed by Ehrlich cells and the MRP/PLF sequences 
deduced so far. Thus, mRNA samples from in vivo and 
cultured Ehrlich cells were used for RT/PCR experi- 
ments using primers designed to amplify the entire open 
reading frames encoding MRP/PLFs. After separation 
of the PCR products in agarose gels, two different bands 
were detected by ethidium bromide staining (Fig. 4A): 
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Fig. 3. Evolution of the PLF mRNA levels during primary cultures of 
Ehrlich tumor cells. (A) Total cell numbers obtained at different times 
after seeding of freshly harvested Ehrlich cells at plateau phase of 
growth (2.5 x IO5 cells/ml). (B) Northern analysis of RNA from Ehrlich 
cells collected at different times during primary cultures: seeded cells 
(lane I), hour 6 (lane 2), hour 12 (lane 3), hour 24 (lane 4), hour 48 (lane 
5). A single membrane was hybridized to cDNA probes for PLF and 
GAPDH. Relative hybridization signals for PLF mRNA normalized 
to those of GAPDH were: 1 (hour 0), 0.62 (hour 6) 0.65 (hour 12), 0.21 
(hour 24) 0.08 (hour 48). 
the major band (about 80% after densitometric analysis) 
had the predicted size (about 760 bp) for amplification 
products containing the full PLF coding sequences. The 
minor band had a shorter size (about 650 bp), but was 
also recognized by the PLF-2 probe by Southern blotting 
(results not shown). The existence of two PLF-hybridiza- 
ble messengers with different lengths could contribute to 
the smear band which is observed in Northern blots 
(Figs. l-3). 
After PstI digestion and subcloning of the amplifica- 
tion products, three regular size-inserts (704 bp: PLF-AI, 
PLF-AIL PFL-BI) and two short size inserts (596 bp: 
sPLF-A and sPLF-B) were sequenced. The deduced pol- 
ypeptide sequences encoded by PLF-AI and PLF-BI 
were identical to those of PLF-1 [l]. PLF-AI1 only pre- 
sented three puntual base substitutions with respect to 
PLF-1 (Fig. 4B); Ala”’ being the only PLF-2 character- 
istic residue [ 161 detected. These simple substitutions 
could either reflect real differences occurring in these 
hyperdiploid cells or have been introduced by polym- 
erase during amplification. The differences among the 
three MRP/PLF sequences deduced so far are also 
caused by substitutions of 3 (MRP/PLF 3) or 5 (PLF-2) 
puntual bases with respect to the PLF- 1 cDNA sequence 
[10,16]. The deduced sequences encoded by the short 
inserts (Accession Number in EMBL Data Bank X- 
75557) are also shown in Fig. 4B; they also correspond 
to PLF-1 sequences but lack the entire sequence encod- 
ing for amino acid residues 70-105, that are present in 
every MRP/PLF deduced so far. Hence, the translation 
product of these short mRNAs (sPLF) would lack two 
potential glycosylation sites and one of the most turn- 
enriched hydrophilic fragments present in MRP/PLFs. 
This delection could bring together two a-helix segments 
predicted for rodent prolactin-like proteins [ 121. In addi- 
tion, Cyss7 (Cys’* in the mature PLFs), which is a con- 
served residue among every member of the mouse GHI 
PRL family [12,23] would be absent in the translation 
product of sPLF mRNAs. This Cys residue seems to be 
involved in disulphide bonds in MPR/PLFs and other 
members of the family [23]. These changes should lead 
to significant variations in the sPLF properties for mac- 
romolecular interaction with respect to other reported 
MRP/PLFs. 
On the other hand, the deleted residues encoding for 
amino acids 70-105 correspond exactly to those of the 
exon 3 of a mrplplf genomic clone named mrplplf 3 by 
Connor et al. [lo]. The genomic organization of the other 
mrplplf genes seems to be similar [5,10]. It is noteworthy, 
that the beginning of the reported exon 3, is also the 
point in which a major gap is observed when alignment 
is carried out among placental proliferin-related protein 
(PRP) and the other members of the GH/PRL family 
[12]. Altered forms of other members of this family have 
been reported; for instance, the 22 and 20 kDa forms of 
the pituitary human GH are products of an alternative 
splicing of a human GH gene, the 20 kDa GH being 
about 10% of the synthetized hormone [24]. The high 
degree of identity between PLF-1 and sPLF sequences, 
and the location of the deleted fragment in the shorter 
one, would be in keeping with the occurrence of an alter- 
native splicing process of the primary PLF transcripts in 
Ehrlich carcinoma cells. Linzer and Wilder observed dif- 
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Fig. 4. Different RT/PCR amplification products obtained from Ehrlich cell samples. (A) Analysis by agarose lectrophoresis and ethidium bromide 
staining of 10 PI/lane of RT/PCR products (22 cycles) from mRNA samples obtained from cells harvested at plateau-phase of growth in vivo (lane 
I), and the same cells growing in vitro after 12 h of primary culture (lane 2). In both cases, all of the mRNA extracted from I x IO6 cells was used 
for RT/PCR in a final volume of 100 ~1. HaeIII-digested 9X-174 was used as standard (lane St). (B) Deduced amino acid sequences encoded by 
MRPlPLF mRNAs of Ehrlich cells. The fragment not encoded by sPLF is shadowed. Potential glycosylation sites are in boxes. Cys residues are 
marked with asterisks. Horizontal arrows underline the highest surface probability fragments. Vertical arrows indicate the exon junction sites in the 
mrplplfmature transcripts [IO]. The amino acid substitutions respect o PLF-1 found in two of the five sequenced clones are shown on the sequence 
at their respective positions; PLF-AH: Thr6 (ACT), Va199 (GTA), Ala”” (GCA); and sPLF-A: GIY’“~ (GCT). 
ferences in mrplplf transcript processing between resting 
and serum-stimulated 3T3 fibroblasts [14]. More re- 
cently, Malyankar et al. [5] report that alterations in the 
processing pathway play a critical role in MPR/PLF 
transcript stability during cultured murine fibroblast im- 
mortalization. Nevertheless, the existence of shorter 
MRP/PLF mRNA variants has not been observed on 
mouse fibroblasts [5,14]. The occurrence of these differ- 
ent MRP/PLF-related open reading frames in Ehrlich 
carcinoma cells seem to be a growth-independent fact, 
since the same amplification pattern was obtained with 
cells in plateau-phase of growth and cells growing in 
culture for 12 h (Fig. 4a). 
In conclusion, in this letter we communicate for the 
first time the occurrence of difference PLF-l-related 
mRNAs in Ehrlich carcinoma cells. In addition, the ex- 
pression of these MRPlPLF mRNAs do not seem to be 
related to cell growth in this model. Repressors of MRP/ 
PLF expression (i.e. glucocorticoids, TGF-jl) [2] could 
also operate during lag and exponential phase of growth 
in vivo. In fact, tumor transplantation of Ehrlich cells is 
brought about using cells expressing MRP/PLF actively 
(day lo-day 12). Ehrlich carcinoma-bearing mice are 
well-characterized in terms of host-tumor interactions 
[17,18,25]. In addition, since Ehrlich cells proliferate in 
serum-free culture media, individual effects of hormones, 
mitogens and growth factors on the MRP/PLF expres- 
sion could be clearly observed and correlated with the 
results obtained in vivo. Thus, Ehrlich carcinoma seem 
to be a good model for studying the physiological role 
and the control of the expression of these proteins in 
transformed cells. 
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